China Pharma (CPHI) vs Impact BioMedical (IBO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Impact BioMedical (IBO) has outperformed China Pharma (CPHI) over the past year, losing 42.7% versus a loss of 56.6%. China Pharma is the larger company by market cap ($41.3 million vs $35.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | IBO |
|---|---|---|
| Share price | $0.96 | $4.11 |
| Market cap | $41.30M | $35.11M |
| 1-day change | +12.94% | -8.26% |
| YTD return | -29.75% | -29.92% |
| 1-year return | -56.63% | -42.73% |
| 5-year return | -99.69% | — |
| P/E ratio (TTM) | — | 0.37 |
| EPS (TTM) | $-0.42 | $11.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $10.51 |
| 52-week low | $0.38 | $4.10 |
| Distance from 52-week high | -95.00% | -60.88% |
| Average volume | 5.47M | 11.61K |
| Shares outstanding | 43.02M | 8.54M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBO has outperformed CPHI by 13.9 percentage points over the past year.
CPHI vs IBO FAQ
Which is bigger, China Pharma or Impact BioMedical?
China Pharma (CPHI) is larger, with a market capitalization of $41.30M compared with $35.11M for Impact BioMedical (IBO).
Which stock has performed better over the past year, CPHI or IBO?
IBO returned -42.73% over the past 12 months, compared with -56.63% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Impact BioMedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.